Table 2.
Demographic characteristics of RB patients with different hope scores (N = 317)
| Characteristics | N (%) | hope score | F-value /t-value | P-value |
|---|---|---|---|---|
| Age, years | ||||
| ≤ 2 | 60(18.93) | 35.82 ± 4.15 | 0.337* | 0.799 |
| > 2,≤3 | 90(28.39) | 35.09 ± 3.57 | ||
| > 3,≤5 | 117(35.91) | 35.30 ± 4.85 | ||
| > 5 | 50(15.78) | 35.44 ± 5.10 | ||
| Sex | ||||
| Male | 167(52.68) | 35.06 ± 4.94 | −1.294# | 0.197C |
| Female | 150(47.32) | 35.69 ± 3.74 | ||
| Time since diagnosis, months | ||||
| ≤ 6 | 44(13.88) | 36.02 ± 4.72 | 0.930* | 0.447 |
| > 6,≤12 | 65(20.50) | 35.09 ± 4.06 | ||
| > 12,≤24 | 102(32.18) | 35.65 ± 4.29 | ||
| > 24,≤36 | 75(23.66) | 35.28 ± 4.40 | ||
| > 36 | 31(9.78) | 34.23 ± 5.14 | ||
| Ocular disease | ||||
| Monoculus | 225(70.98) | 35.52 ± 4.27 | −2.303# | 0.022C |
| Binoculus | 92(29.02) | 34.97 ± 4.76 | ||
| Tumor stage at diagnosisa | ||||
| A/B/C | 15(4.73) | 35.80 ± 3.12 | 0.580* | 0.629 |
| D | 132(41.64) | 35.43 ± 4.38 | ||
| E | 156(49.21) | 35.14 ± 4.55 | ||
| Extraocular | 14(4.42) | 36.64 ± 4.60 | ||
| Treatment types b | ||||
| ≤ 4 | 131(41.32) | 34.90 ± 4.61 | 2.972* | 0.053 |
| 4–6 | 158(49.84) | 35.94 ± 4.36 | ||
| > 6 | 28(8.84) | 34.25 ± 3.42 | ||
| Times of hospitalizations | ||||
| ≤ 6 | 110(34.70) | 35.36 ± 4.26 | 1.650* | 0.194 |
| 6–10 | 94(29.65) | 35.97 ± 4.31 | ||
| > 10 | 113(35.65) | 34.85 ± 4.64 | ||
| Disease state | ||||
| Under treatment | 108(34.07) | 34.72 ± 4.09 | 1.711* | 0.182 |
| Under reexamine | 206(64.98) | 35.69 ± 4.59 | ||
| Had cured | 3(0.95) | 35.60 ± 7.58 | ||
Note. N Number; * = F value; # = t value; Bold face p < 0.05.
aintraocular retinoblastoma was classified by the International Classification of Retinoblastoma as group A; group B; group C; group D; and group E.
bthe sum of the treatment types methods (such as intravenous chemotherapy, intra-arterial chemotherapy, examination under anesthesia, enucleation, intracameral chemotherapy, intravitreal chemotherapy, cataract surgery, onsolidation therapies, pars plana vitrectomy, anti-neovasculariztion therapy, and cradiation-based therapies) that have been used so far.
CP-values calculated from Independent sample t-test; all other P-values were obtained by using the One-way ANOVA test.